Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA1 | P00915 | 2/20 | 0.58 |
| ▸ | CA2 | P00918 | 2/20 | 0.58 |
| ▸ | SRC | P12931 | 1/20 | 0.45 |
| ▸ | ERN1 | O75460 | 2/20 | 0.44 |
| ▸ | TLR2 | O60603 | 1/20 | 0.44 |
| ▸ | TLR1 | Q15399 | 1/20 | 0.44 |
| ▸ | TLR6 | Q9Y2C9 | 1/20 | 0.44 |
| ▸ | MCL1 | Q07820 | 1/20 | 0.40 |
| ▸ | NFE2L2 | Q16236 | 2/20 | 0.40 |
| ▸ | LMNA | P02545 | 3/20 | 0.39 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.39 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.39 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.39 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.39 |
| ▸ | BLM | P54132 | 2/20 | 0.38 |
| ▸ | MEN1 | O00255 | 1/20 | 0.38 |
| ▸ | THRB | P10828 | 1/20 | 0.38 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.38 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.38 |
| ▸ | TSHR | P16473 | 2/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1252425 | 0.82 | CA1 (0.42) | CA1CA2SRCLMNAALDH1A1 | |
| SCHEMBL2787203 | 0.82 | CA1 (0.73) | CA1CA2SRCERN1TLR2 | |
| SCHEMBL1446630 | 0.82 | CA1 (0.42) | CA1CA2SRCERN1TLR2 | |
| SCHEMBL14999530 | 0.81 | NFE2L2 (0.40) | CA1CA2NFE2L2LMNACYP1A2 | |
| SCHEMBL16959642 | 0.81 | GABRA1 (0.42) | CA1CA2NFE2L2LMNACYP1A2 | |
| SCHEMBL15003032 | 0.80 | NFE2L2 (0.45) | CA1CA2NFE2L2LMNACYP1A2 | |
| SCHEMBL1253571 | 0.80 | ALDH1A1 (0.41) | CA1CA2ERN1ALDH1A1TSHR | |
| SCHEMBL5548772 | 0.80 | GABRA1 (0.50) | CA1CA2LMNACYP1A2ALDH1A1 | |
| SCHEMBL16253608 | 0.77 | NFE2L2 (0.37) | CA1CA2NFE2L2LMNACYP1A2 | |
| SCHEMBL11440560 | 0.77 | CA1 (0.61) | CA1CA2SRCERN1TLR2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 17 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20070027215-A1 | Nuclear receptor ligands and ligand binding domains | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2007-02-01 | — | — | US | disclosed |
| EP-0873361-B1 | Crystals of the ligand-binding domain of the thyroid hormone receptor complexed to a ligand | UNIV CALIFORNIA (US) | 2006-11-02 | — | — | EP | disclosed |
| US-7122579-B2 | Eye treatments using synthetic thyroid hormone compositions | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2006-10-17 | — | — | US | disclosed |
| US-20030175849-A1 | Eye treatments using synthetic thyroid hormone compositions | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA | 2003-09-18 | — | — | US | disclosed |
| WO-2003039456-A2 | PROCESS FOR THE PREPARATION OF ANILINE-DERIVED THYROID RECEPTOR LIGANDS | BRISTOL-MYERS SQUIBB COMPANY (US) | 2003-05-15 | — | — | WO | disclosed |
| US-6555582-B1 | Topically applying a synthetic thyroid hormone to inhibit hyaluronic acid secretion to treat elevated intraocular pressure and glaucoma | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA | 2003-04-29 | — | — | US | disclosed |
| EP-0873361-A4 | NUCLEAR RECEPTOR LIGANDS AND LIGAND BINDING DOMAINS | UNIV CALIFORNIA (US) | 2002-10-23 | — | — | EP | disclosed |
| EP-1003530-A4 | EYE TREATMENTS USING SYNTHETIC THYROID HORMONE COMPOSITIONS | UNIV CALIFORNIA (US) | 2001-10-04 | — | — | EP | disclosed |
| US-6236946-B1 | Nuclear receptor ligands and ligand binding domains | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2001-05-22 | — | — | US | disclosed |
| EP-1034184-A2 | NUCLEAR RECEPTOR LIGANDS AND LIGAND BINDING DOMAINS | The Regents of the University of California (US) | 2000-09-13 | — | — | EP | disclosed |
| EP-1003530-A1 | EYE TREATMENTS USING SYNTHETIC THYROID HORMONE COMPOSITIONS | The Regents of the University of California (US) | 2000-05-31 | — | — | EP | disclosed |
| US-6054485-A | FOR TREATMENT OF GLAUCOMA | REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2000-04-25 | — | — | US | disclosed |
| WO-1999026966-A2 | NUCLEAR RECEPTOR LIGANDS AND LIGAND BINDING DOMAINS | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 1999-06-03 | — | — | WO | disclosed |
| EP-0873361-A2 | NUCLEAR RECEPTOR LIGANDS AND LIGAND BINDING DOMAINS | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 1998-10-28 | — | — | EP | disclosed |
| WO-1998007435-A9 | EYE TREATMENTS USING SYNTHETIC THYROID HORMONE COMPOSITIONS | — | 1998-08-06 | — | — | WO | disclosed |
| WO-1998007435-A1 | EYE TREATMENTS USING SYNTHETIC THYROID HORMONE COMPOSITIONS | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 1998-02-26 | — | — | WO | disclosed |
| WO-1997021993-A2 | NUCLEAR RECEPTOR LIGANDS AND LIGAND BINDING DOMAINS | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 1997-06-19 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070027215-A1 | Nuclear receptor ligands and ligand binding domains | TSHR, NR5A2, THRA | CA1 4530/4885CA2 4453/4885SRC 630/4885 |
| US-20030175849-A1 | Eye treatments using synthetic thyroid hormone compositions | ADAMTS5, TRHDE, ADAMTS1 | CA1 815/4885CA2 372/4885SRC 3713/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.